Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Dec;94(12):1303-1305.
doi: 10.1002/ajh.25662. Epub 2019 Nov 7.

A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!

Michele Merli  1 , Francesco Passamonti  1   2
Affiliations
Free article
Comment

A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!

Michele Merli et al. Am J Hematol. 2019 Dec.
Free article
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019. https://doi.org/10.1002/ajh.25638. [Epub ahead of print].
    1. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus Ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223. https://doi.org/10.1056/NEJMoa1400376.
    1. Byrd JC, Hillmen P, Brien SO, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133(19):2031-2043.
    1. Brien SO, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia : a 5-year experience. Blood. 2019;131(17):1910-1920.
    1. Fischer K, Cramer P, Busch R, et al. Bendamustine combined With rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol. 2011;29(26):3559-3566. https://doi.org/10.1200/JCO.2010.33.8061.